Skip to content
Open access

Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer

Sep 2026 · Journal of Experimental & Clinical Cancer Research · 0 citations

TL;DR

Findings delineate a ferroptosis–ICD–immune axis underlying the antitumor activity of RC48 and support its clinical development as a monotherapy or in combination with immune checkpoint inhibitors for HER2-expressing breast cancer.

Abstract

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly aggressive and is associated with poor prognosis after metastasis or recurrence. The development of anti-HER2 antibody–drug conjugates (ADCs) has markedly improved outcomes. Disitamab vedotin (RC48) is a novel anti-HER2 ADC that exhibits antitumor activity against both HER2-positive and HER2-low breast cancers, although its molecular mechanism of action remains incompletely understood. Here, we show that RC48 triggers the accumulation of lipid reactive oxygen species (ROS), thereby inducing ferroptosis and the subsequent release of damage-associated molecular patterns (DAMPs) that initiate immunogenic cell death (ICD). DAMP emission promotes dendritic cell maturation and increases CD8 + T-cell infiltration and cytotoxicity within the tumor microenvironment. In vivo mouse models confirm the efficacy and safety of RC48 both as a monotherapy and as part of a combination therapy with anti-programmed cell death ligand 1 (PD-L1). Collectively, our findings delineate a ferroptosis–ICD–immune axis underlying the antitumor activity of RC48 and support its clinical development as a monotherapy or in combination with immune checkpoint inhibitors for HER2-expressing breast cancer.

Read PDF

Similar papers

Review Open access Oct 2026

Complement in HER2-Positive Breast Cancer: A Conditionally Protective Mechanism Under Attack

The therapeutic efficacy of anti-HER2 monoclonal antibodies in breast cancer has traditionally been attributed to direct inhibition of signaling and antibody-dependent cellular cytotoxicity (ADCC). Recent evidence, however, has established complement activation through the classical pathway as a possible adjunct mechan...

D. Petkova, Ivaila Kuleva, Zhasmina Stoyanova et al. · 0 citations
Sep 2026

CD20 targeted nanomedicine enhances anti-tumor immunity in diffuse large B-cell lymphoma by activating cGAS/STING pathway.

It is found that PLK4 was up-regulated in DLBCL, and its silencing significantly inhibited tumor growth, and the combination of si-PLK4 and VCR exerted stronger anti-tumor effects than either treatment alone, which was mediated by activating cGAS-STING pathway.

Zuofei Chi, Nan-Nan Xu, Ying Sun et al. · 0 citations
Oct 2026

A Nanodelivery Platform Harnessing Synthetic Lethality and Efferocytosis Inhibition for Synergistically Enhanced Immunotherapy of Triple-Negative Breast Cancer.

Findings indicate that precise molecularly targeted ICD combined with coordinated immune activation enables efficient primary tumor suppression and promotes T-cell phenotypes associated with antitumor immune memory, providing a novel paradigm for cancer immunotherapy.

Hua-Wei Liu, Sheng-Ming Wu, Han Zhou et al. · 0 citations
Sep 2026

Abstract B121: Induction of Immunogenic Cell Death in Pancreatic Ductal Adenocarcinoma by a Sigma-2 Ligand–Conjugated xCT Inhibitor

Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal and is largely resistant to current immunotherapy approaches, in part because of a profoundly immunosuppressive tumor microenvironment (TME) that limits antigen presentation and effector immune cell activity. Immunogenic cell death (ICD) is a regulated...

David Barr, Shub Mehta, John P. Whelchel et al. · 0 citations
Sep 2026

Abstract B144: MUC16-directed DR5 activation by IMV-M induces selective tumor cell apoptosis and tumor regression and enhances the activity of KRAS inhibitors in preclinical pancreatic cancer models

It is demonstrated that IMV-M exhibits potent and selective antitumor activity against MUC16-positive pancreatic cancer models through targeted DR5 activation, supporting the potential development of combination regimens with KRAS-directed therapies that have demonstrated promising clinical activity in pancreatic cance...

Hai-Yong Han, M. Zucker, Sanjana Tripuraneni et al. · 0 citations
Sep 2026

Abstract B047: CXCR4 synergizes with multi-RAS inhibition by overcoming T cell exclusion to enhance immunogenic cancer cell death in human pancreatic cancer slice culture

The multi-RAS inhibitor, daraxonrasib, has demonstrated a remarkable improvement in outcomes for patients with metastatic PDAC. Pre-clinical murine studies have shown that the durable effects of the pre-clinical multi-RAS inhibitor, RMC-7977, require an intact immune system including CD8+ T cells and cross-presen...

Sheela R. Damle, Nancy Liu, Xiu-Yun Jiang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.